Meliglix

Sitagliptin, the active ingredient in Meliglix, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, typically as part of a regimen that includes diet and exercise.

GNH USA supplies Meliglix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions, including the European Union and Asia‑Pacific markets.

Sitagliptin is used to manage hyperglycaemia in the type 2 diabetes therapeutic pathway. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels when used alone with diet and exercise. - Type 2 diabetes mellitus (combination with metformin): provides additional glycaemic reduction in patients inadequately controlled on metformin. - Type 2 diabetes mellitus (combination with insulin): enhances insulin efficacy and may reduce required insulin dose.

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain of varying intensity. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Gastrointestinal discomfort: includes nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: including angioedema, rash or anaphylaxis. - Bullous pemphigoid: autoimmune blistering skin disorder.

When prescribing sitagliptin, clinicians should consider several safety considerations. - Renal function: assess creatinine clearance and adjust dose in moderate to severe impairment. - Hepatic impairment: use with caution in patients with liver disease. - Hypoglycaemia risk: monitor closely when combined with insulin or sulfonylureas. - Cardiovascular disease: evaluate benefits in patients with established heart disease. - Elderly patients: start at lower dose and monitor for adverse effects. - Store at ambient temperature: keep tablets in original container, protect from moisture and excessive heat.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other DPP‑4 inhibitors (e.g., saxagliptin, alogliptin): may increase risk of adverse effects. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce sitagliptin plasma concentrations. - Combination with high‑dose insulin or sulfonylureas: can cause severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may alter glucose homeostasis. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - Beta‑blockers: may mask hypoglycaemia symptoms. - NSAIDs: watch for renal function changes. - Anticoagulants (e.g., warfarin): periodic INR monitoring recommended.